论文部分内容阅读
目的:探讨肺腺癌患者采用培美曲塞联合顺铂治疗的临床疗效和毒副作用。方法:以我院2012年8月至2015年8月收治的66例肺腺癌患者为研究对象,根据患者的自身情况,分别选择培美曲塞联合顺铂治疗(观察组)和紫杉醇联合顺铂治疗(对照组),每组各33例患者。比较分析两组患者的治疗效果、感染发生率和不良反应。结果:两组患者的总缓解率分别为66.67%和42.42%,观察组患者的总缓解率明显高于对照组患者,数据差异具有统计学意义(P<0.05)。两组患者的总感染率分别为51.52%和27.27%,观察组患者的总感染率明显低于对照组患者(P<0.05)。观察组患者不良反应的发生率明显低于对照组患者(P<0.05)。结论:肺腺癌患者采用培美曲塞联合顺铂化疗治疗,能有效提高治疗效果、降低感染率、减少毒副作用。
Objective: To investigate the clinical efficacy and side effects of pemetrexed combined with cisplatin in patients with lung adenocarcinoma. Methods: Sixty-six patients with lung adenocarcinoma admitted from August 2012 to August 2015 in our hospital were enrolled in this study. Pemetrexed combined with cisplatin (observation group) and paclitaxel Platinum treatment (control group), 33 patients in each group. Comparative analysis of two groups of patients with treatment, infection and adverse reactions. Results: The total remission rates of the two groups were 66.67% and 42.42%, respectively. The total remission rate in the observation group was significantly higher than that in the control group, with statistical significance (P <0.05). The total infection rates of the two groups were 51.52% and 27.27%, respectively. The total infection rate in the observation group was significantly lower than that in the control group (P <0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group (P <0.05). Conclusion: Patients with lung adenocarcinoma treated with pemetrexed combined with cisplatin can effectively improve the therapeutic effect, reduce the infection rate and reduce the side effects.